SunNovo

Beijing Sunshine Nohe Drug Research Co., Ltd. (referred to as: SunNovo) was established in 2009 and is one of the earlier Contract Research Organizations (CROs) in China to provide external drug research and development services. As an external resource available to pharmaceutical manufacturing enterprises, after receiving client commissions, the company can quickly organize a highly specialized and experienced research team within a short period of time, thereby helping pharmaceutical companies accelerate drug R&D progress, reduce R&D costs, and achieve high-quality research results. Since 2015, projects in which the company has participated in the R&D have cumulatively obtained 147 clinical approvals or clinical trial registration numbers; one innovative drug has entered Phase III clinical trials, and it is part of the "National Major Science and Technology Project - Major New Drug Creation Project," with another innovative drug entering Phase II clinical trials; 95 drug marketing registration applications have been accepted, and six generic drugs have been the first to obtain drug registration approval or pass the consistency evaluation. In 2017, 2018, and 2019, the company consecutively received the title of "Top 20 Pharmaceutical R&D Company in China" awarded by the All-China Federation of Industry and Commerce Pharmaceutical Chamber of Commerce. As a comprehensive CRO company specializing in "pharmaceutical science + clinical trials," it holds significant market influence. In the future, the company will adhere to its development strategy of building a "generic and innovative combination" and "full-process integrated" drug R&D service platform, committed to assisting domestic pharmaceutical enterprises in accelerating import substitution and independent innovation. The company's specific development plan involves implementing four key projects: a drug innovation R&D platform, an innovative drug PK/PD research platform, a special formulation R&D platform, and a clinical trial service platform. These efforts aim to comprehensively enhance the R&D service levels for both generic and innovative drugs, deepen the company’s strategic depth in the R&D industry chain, offer customers a wider range of more challenging, higher value-added R&D services, increase the proportion of comprehensive service business in the company’s revenue, attract more large-scale pharmaceutical enterprise clients, and build the company into a competitive large-scale R&D service enterprise.